Literature DB >> 15447702

Headache profile in patients with idiopathic hypertrophic cranial pachymeningitis.

Yuh-Jen Wang1, Jong-Ling Fuh, Jiing-Feng Lirng, Shiang-Ru Lu, Shuu-Jiun Wang.   

Abstract

BACKGROUND: Idiopathic hypertrophic cranial pachymeningitis (IHCP) is an uncommon disorder due to localized or diffuse thickening of the dura mater. While headache is the most common manifestation, the clinical characteristics of the headache in IHCP have not been well characterized.
METHODS: From 1996 to 2002, 6 consecutive patients with IHCP presenting with headache were reviewed (3 women, 3 men; mean age: 49 years). Diagnosis was based on characteristic neuroimaging findings and the exclusion of secondary causes of cranial pachymeningitis. This study reported the headache characteristics, neuroimaging features, and longitudinal follow-up.
RESULTS: Chronic daily headache, especially chronic migraine, was the most common headache pattern observed (4/6 patients). Lateralization of headache location appeared to correlate with the distribution of the hypertrophied dural lesions. Diagnostic delay was due to failure to evaluate with gadolinium-enhanced MRI. After treatment, headache (5/6, 83%) and neurologic deficits (2/3, 67%) improved in most patients; however, follow-up MRIs (n = 5) showed deterioration in 3 patients.
CONCLUSION: The headache of IHCP is typically a chronic daily headache, often resembling chronic migraine. Correspondingly, IHCP should be considered in the differential diagnosis of refractory chronic daily headache, with or without associated cranial neuropathy or other associated neurologic deficits. The typical imaging finding on gadolinium-enhanced MRI is localized or diffuse pachymeningitis and failure to order a gadolinium-enhanced MRI is the primary reason for delayed diagnosis. Despite symptomatic improvement on longitudinal follow-up, the MRI abnormalities may not improve in parallel with the clinical symptoms.

Entities:  

Mesh:

Year:  2004        PMID: 15447702     DOI: 10.1111/j.1526-4610.2004.04175.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  9 in total

1.  Idiopathic hypertrophic cranial pachymeningitis presenting as acute painless visual loss.

Authors:  Rashmi G Mathew; Kieran M Hogarth; Andrew Coombes
Journal:  Int Ophthalmol       Date:  2012-02-21       Impact factor: 2.031

Review 2.  An approach to the patient with painful ophthalmoplegia, with a focus on Tolosa-Hunt syndrome.

Authors:  Jonathan P Gladstone
Journal:  Curr Pain Headache Rep       Date:  2007-08

Review 3.  [Hypertrophic cranial pachymeningitis as a rare cause of headache].

Authors:  J Kuhn; A Harzheim; S Riku; W Müller; H Bewermeyer
Journal:  Nervenarzt       Date:  2006-04       Impact factor: 1.214

4.  Characteristics of hypertrophic pachymeningitis in patients with granulomatosis with polyangiitis.

Authors:  Hyun Ah Choi; Mi Ji Lee; Chin-Sang Chung
Journal:  J Neurol       Date:  2017-02-20       Impact factor: 4.849

5.  Hypertrophic pachymeningitis.

Authors:  Tomasz Dziedzic; Jakub Wojciechowski; Arkadiusz Nowak; Andrzej Marchel
Journal:  Childs Nerv Syst       Date:  2015-03-15       Impact factor: 1.475

Review 6.  Vertigo and autoimmunity.

Authors:  Roberto Bovo; Andrea Ciorba; Alessandro Martini
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-10-16       Impact factor: 2.503

7.  Infiltrative mass of the skull base and nasopharynx: A diagnostic conundrum.

Authors:  Manish M George; Jay Goswamy; Kohmal Solanki; Rajiv Bhalla
Journal:  Ann Med Surg (Lond)       Date:  2015-03-30

8.  Idiopathic hypertrophic pachymeningitis with anticardiolipin antibody: A case report.

Authors:  Chi-Shun Wu; Hung-Ping Wang; Sheng-Feng Sung
Journal:  Medicine (Baltimore)       Date:  2021-01-15       Impact factor: 1.817

Review 9.  Idiopathic hypertrophic cranial pachymeningitis treated by oral methotrexate: a case report and review of literature.

Authors:  T Bosman; C Simonin; D Launay; S Caron; A Destée; L Defebvre
Journal:  Rheumatol Int       Date:  2007-12-19       Impact factor: 2.631

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.